HealthVerity and Medidata Announce Strategic Partnership to Advance Real World Evidence During and After Clinical Trials

With HealthVerity patient identity technology available across the Medidata platform, real world data is now readily accessible for patient safety monitoring, trial design and long-term therapeutic efficacy beyond the duration of clinical trials.

HealthVerity, the leader in privacy-protected data exchange, announced a strategic collaboration with Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions to support the entire clinical development process, to significantly expand the understanding of clinical trial populations for enhanced insights during and post trial. With heightened necessity stemming from COVID-19, Medidata and HealthVerity have brought together their platforms, expertise and access to data to shape the effectiveness, design and impact of more real-time research. This collaboration will drive better patient outcomes in ongoing and prospective clinical trials, while delivering effectiveness and safety evidence reflective of populations beyond clinical trials.

This expanded partnership builds on the application of HealthVerity Census, the industry’s only real-time patient identity resolution technology, applied across the Medidata Rave Clinical Cloud, the end-to-end clinical research platform, supporting more than 22,000 studies. With the unique and consistent patient identifier, the HealthVerity ID (HVID), available across the platform, researchers are now able to integrate patient-consented trial or registry data with traditional and novel real world data such as claims, EMR, labs, chargemaster, consumer, wearable sensors, digital interventions, and social determinants of health for studies at large.

Recommended AI News: Drone Racing League And Genius Sports Set The Stage For Sports Betting

We are witnessing the power of clinical trial and real-world data linkage in improving outcomes across disease areas.

“We are witnessing the power of clinical trials and real world data linkage in improving patient outcomes across disease areas. This advancement is occurring in multiple settings, and is potentially applicable in thousands of studies Medidata currently supports. We are seeing increasing interest especially across oncology and rare diseases where hybrid studies can meaningfully impact patient access to therapies,” said Arnaub Chatterjee, Senior Vice President of Product for Acorn AI, by Medidata, a Dassault Systèmes company. “We’re excited to expand upon our relationship with HealthVerity to enable life sciences companies to use RWD throughout the clinical development process.”

Recommended AI News: Black-Owned SaaS Company CredKred Launches To Put Power Of Credit Repair Back In Consumer Hands

“The potential to combine HealthVerity’s leading ecosystem of 330 million patients from more than 75 healthcare and consumer sources with patient-level clinical trial data supported by Medidata, can benefit not only post-market clinical trial safety and effectiveness studies but can even be fed back into the design of the trial itself,” said Sandy Leonard, Vice President of RWE Platforms at HealthVerity. “Our commitment to decreasing the friction of technology and enabling the greater use of real-world data is exemplified with the pre-enabled linkage we now have with Medidata’s platform.”

Recommended AI News: TreasuryXpress Receives The IDC 2020 SaaS TMS Customer Satisfaction Award